It has been just over a year since we reported how oncogene-driven patient advocacy groups are disrupting the research paradigm in lung cancer.1 We have indeed come a long way […] Read more
Patients and supporters cycled nearly 1,150 kilometers through The Netherlands on May 21, 2021 in a “White Ribbon Tour” to raise awareness for lung cancer. The grassroots event was organized […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 Over the past decade, lung cancer has emerged as a shining example of how precision medicine can dramatically improve patient outcomes. Up […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 An exploratory analysis of circulating free DNA (cfDNA) shows that lorlatinib confers potent antitumor activity in pretreated patients with ALK-positive NSCLC regardless […] Read more
By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field […] Read more
By Robert C. Doebele, MD, PhD Posted: December 11, 2019 Dr. Robert C. Doebele Early in the drug development of targeted therapies, specific oncogene mutations were often associated with a […] Read more